Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

GRAL - GRAIL, Inc. So'nggi Yangiliklar | Finranks

Home

GRAL

G

GRAIL, Inc. (GRAL)

NMS – Real vaqt narxi. Valyuta: USD

48.49

-3.67 (-7.04%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

48.30

-0.19 (-0.39%)

Bozordan keyin: Mar 27, 2026, 7:59 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Videolar

Trump Media CEO: 'NUCLEAR FUSION is the HOLY GRAIL'

Press-relizlar

GRAL DROPS ~50% -- REPORTED NUMBERS VS. ACTUAL RESULTS; LEVI & KORSINSKY, LLP INVESTIGATES

GRAL DROPS ~50% -- REPORTED NUMBERS VS. ACTUAL RESULTS; LEVI & KORSINSKY, LLP INVESTIGATES

Grail told investors cash burn would be no more than $290 million while guiding to milestones the Company may have known were at risk NEW YORK, March 25, 2026 /PRNewswire/ -- Grail, Inc. (NASDAQ: GRAL) investors lost approximately half the value of their holdings when the stock plunged roughly 50% following disclosure that the NHS Galleri trial missed its primary endpoint. If you lost money on GRAL, submit your information now to discuss your legal rights.

LEVI & KORSINSKY, LLP: GRAIL (GRAL) GUIDED TO 2030 CASH RUNWAY WHILE KEY TRIAL RISK WENT UNADDRESSED

LEVI & KORSINSKY, LLP: GRAIL (GRAL) GUIDED TO 2030 CASH RUNWAY WHILE KEY TRIAL RISK WENT UNADDRESSED

Investigation examines whether Grail's forward guidance omitted material headwinds known to management at the time NEW YORK, March 18, 2026 /PRNewswire/ -- Grail, Inc. (NASDAQ: GRAL) lost approximately 50% of its market value after disclosing that the NHS Galleri randomized trial failed to meet its primary endpoint. Shareholders who lost money on GRAL are encouraged to submit their information now.

GRAIL Announces Retirement of CEO Bob Ragusa and Appointment of Josh Ofman, MD, MSHS, as Successor

GRAIL Announces Retirement of CEO Bob Ragusa and Appointment of Josh Ofman, MD, MSHS, as Successor

MENLO PARK, Calif., March 12, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that Bob Ragusa will retire as Chief Executive Officer, effective June 1, 2026.

Levi & Korskinsky, LLP: Grail (GRAL) Guided to 2030 Cash Runway While Key Trial Risk Went Unaddressed

Levi & Korskinsky, LLP: Grail (GRAL) Guided to 2030 Cash Runway While Key Trial Risk Went Unaddressed

Investigation examines whether Grail's forward guidance omitted material headwinds known to management at the time Investigation examines whether Grail's forward guidance omitted material headwinds known to management at the time